United Kingdom

UK First in Europe to Dispense Lilly's Weight-Loss Pill

Is the U.K.'s approval of orforglipron a medical breakthrough or a shortcut that will backfire?

10 hours ago·Updated 8 hours ago

UK First in Europe to Dispense Lilly's Weight-Loss Pill

Story

Above: Packaging for the Foundayo weight loss oral pill. Image credit: Michael Siluk/UCG/Universal Images Group/Getty Images

The Spin

Narrative A

The U.K.’s approval of orforglipron is a massive win for those struggling with obesity. This once-daily pill, with no food or water restrictions, has been proven to deliver nearly 12.5% weight loss in trials and finally gives patients a flexible, accessible option. This approval is a step in the right direction.

Eli Lilly and Company GOV.UK

Narrative B

While obesity pills like orforglipron deliver real weight loss, they also bring real trade-offs, including more side effects, lean muscle loss and no proven quality-of-life gains at the one-year mark. Fundamentally, they fail to address the root causes driving obesity rates higher every decade: an unhealthy lifestyle, which only exercise, diet and environmental changes can fix.

NPR BMJ